For the Treatment of Hyperinsulinemias
We are developing a new class of oral selective nonpeptide somatostatin type 5 receptor, or sst5, agonists designed to treat congenital hyperinsulinism, or CHI. This is a devastating rare disease in which infants are born with mutations that cause excess secretion of the pancreatic hormone insulin resulting in profound hypoglycemia, a very low level of blood glucose. This loss of homeostatic control of blood glucose levels can lead to seizures, developmental disorders, learning disabilities, coma and even death. CHI occurs in approximately 1 in 30,000 to 50,000 new births in the United States.
We conducted first-in-human enabling studies with our first product candidate, CRN02481. Due to a toxicity finding that we believe was specific to CRN02481, we are advancing new molecules through preclinical activities with the goal of selecting a new product candidate for CHI.